Efficacy Study of GLYC-101 to Evaluate Outcomes After Post-laser Ablation (NCT00656474) | Clinical Trial Compass
CompletedPhase 1/2
Efficacy Study of GLYC-101 to Evaluate Outcomes After Post-laser Ablation
United States12 participantsStarted 2008-03
Plain-language summary
Study is intended to evaluate safety and efficacy parameters in patients treated with GLYC-101 gel or placebo after laser ablation.
Who can participate
Age range25 Years – 65 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
Subjects meeting all of the following criteria will be considered for admission to the study:
* Patients giving informed consent for retro-auricular laser ablation between 25 and 55 years old.
* Retro-auricular area is free of any irritation, scars or dermatologic conditions which might interfere with the study.
* Willing and able to participate in the study and follow all study directions.
* Able to read, understand and sign the consent form.
Exclusion Criteria:
* Pregnant, nursing, or planning a pregnancy during the course of the study, as determined by the interview and a urine pregnancy test.
* Systemic or cutaneous disease that may interfere with the study results.
* Presence of irritation or dermatologic skin conditions in the retro-auricular area.
* Known allergies to materials within the test formulations.
* Systemic or cutaneous therapy with medication that impacts wound healing (steroids, immune modulators, immune suppressants).
What they're measuring
1
Time to Complete Wound Closure (Epithelialization)
Timeframe: Over the course of 1 month following the initial treatment.